Trinity Biotech Says It Is Targeting Approximately $20M Of Annualized Run-rate EBITDA On Annualized Run-rate Revenues Of Approximately $75M By Q2, 2025
Trinity Biotech Says It Is Targeting Approximately $20M Of Annualized Run-rate EBITDA On Annualized Run-rate Revenues Of Approximately $75M By Q2, 2025
Trinity Biotech表示，其目标是到2025年第二季度实现约2,000万美元的年化运行利率息税折旧摊销前利润，而年化运行利率收入约为7500万美元
The company said this outlook is predicated solely on growth from the existing businesses including haemoglobin testing and HIV, and planned improvements to operating margins, with no contribution from the recently acquired biosensor business.
该公司表示，这一前景完全取决于包括血红蛋白检测和艾滋病毒在内的现有业务的增长，以及计划提高营业利润率，而最近收购的生物传感器业务没有任何贡献。